Search Browse Earnings

Candel Therapeutics, Inc. — SlamSEC

Candel Therapeutics, Inc.

Nasdaq:CADL

Biological Products, (No Diagnostic Substances)·NEEDHAM, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$125,000

+0.0% YoY

FY 2023

Adj. EBITDA

-$38.2M

-30527.2% margin

FY 2024

Net Income

-$37.9M

-30351.2% margin

FY 2024

EPS (Diluted)

-$1.31

FY 2024

Stock Price

$5.10

-0.1%

2026-03-11

52W Range

$4.25 – $9.08

P/E Ratio

-3.9x

Market Cap

$280.0M

Cash

$35.4M

FY 2024

Total Debt

$1.7M

FY 2024

Net Cash

$33.7M

FY 2024

Enterprise Value

$246.3M

Debt / EBITDA

0.9x

FY 2023

EV / EBITDA

-6.5x

Employees

—